VistaGen Therapeutics(VTGN)

Search documents
VistaGen Therapeutics(VTGN) - 2021 Q1 - Quarterly Report
2020-08-13 20:26
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (State or other jurisdiction of incorporation or organization) Nevada 20-5093315 (I.R.S. Emplo ...
VistaGen Therapeutics(VTGN) - 2020 Q4 - Annual Report
2020-06-29 22:34
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: March 31, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 343 Allerton Avenue South S ...
VistaGen Therapeutics(VTGN) - 2020 Q3 - Quarterly Report
2020-02-13 21:36
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 Nevada 20-5093315 (I.R.S. Employer Identification No.) 343 Allerton Avenue South San Francisco, CA 94080 (Address of p ...
VistaGen Therapeutics(VTGN) - 2020 Q2 - Quarterly Report
2019-11-07 00:57
For the transition period from to . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of in ...
VistaGen Therapeutics(VTGN) - 2020 Q1 - Quarterly Report
2019-08-13 20:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...
VistaGen Therapeutics(VTGN) - 2019 Q4 - Annual Report
2019-06-25 20:17
or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-37761 VistaGen Therapeutics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: March 31, 2019 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 20-5093315 343 Aller ...
VistaGen Therapeutics (VTGN) Investor Presentation - Slideshow
2019-03-19 15:53
VistaGen® | --- | --- | --- | --- | --- | |-------|----------------------------------------------|-------|-------|------------------| | | | | | | | | | | | | | | LOOKING BEYOND CURRENT | | | | | | | | | | | | TREATMENTS FOR | | | | | | CENTRAL NERVOUS SYSTEM (CNS) | | | | | | DISEASES AND DISORDERS WITH HIGH UNMET NEED | | | www.vistagen.com | | | :VTGN | | | Spring 2019 | vistagen.co m www.vistagen.comForward-looking www.Statements This presentation contains "forward-looking statements" within the meaning ...
VistaGen Therapeutics(VTGN) - 2019 Q3 - Quarterly Report
2019-02-12 21:34
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inc ...